PCAC Recommended Both BPC-157 and TB-500. That's Not a Stacking Protocol.

BPC-157 and TB-500 were reviewed at the July 23–24, 2026 PCAC meeting. On July 23, 2026, the committee recommended BPC-157 for inclusion on the 503A Bulk Drug Substances List, 8-6 with one abstention; TB-500 got its own separate ballot the same day and was also recommended for inclusion, also 8-6 with one abstention. FDA final action is pending on both. No human trial has tested either peptide in combination. BPC-157’s human record comprises a 2025 two-person safety pilot; TB-500 has no published human trials of any kind. A shared recommendation is not a combination endorsement.

What is PCAC’s role in evaluating BPC-157 and TB-500?

The Pharmacy Compounding Advisory Committee doesn’t approve drugs. It advises the FDA on whether a bulk substance belongs on the Section 503A list, the list that lets a compounding pharmacy legally handle a peptide without an approved drug application behind it. BPC-157 and TB-500 were both on the July 23 agenda, alongside KPV and MOTs-C. The July 24 session, a separate day with its own votes, covered Emideltide (also known as DSIP), Semax, and Epitalon. Seven substances, two days, one meeting — grouping by scheduling, not by pharmacology. Legal-trade coverage of the session reports KPV recommended alongside BPC-157, but no outcome for MOTs-C, Emideltide, Semax, or Epitalon has been made public yet; FDA’s own per-substance tally sheet hasn’t posted.

A PCAC recommendation isn’t the FDA saying either peptide works. It’s the committee saying the legal question, whether a pharmacy can handle the substance at all, is worth a yes. No FDA-approved drug application, no NDA and no BLA, exists for either compound, and a recommendation isn’t one — FDA final action is still pending, realistically into 2027. Two names recommended on the same day is still an accident of scheduling, not a combination protocol. The committee didn’t vote on a stack. It voted on two separate agenda items.

Does the mechanistic case for stacking BPC-157 and TB-500 hold up?

The pitch sounds tidy from a distance. BPC-157 is theorized to grow new blood vessels at an injury site. TB-500 is the synthetic version of thymosin beta-4, a small protein your own cells make that binds actin, the scaffolding inside a cell that lets it move and hold its shape. One recruits blood supply. The other, in theory, recruits repair cells into the wound. New vessels plus mobilized cells sounds like two halves of the same job.

No study has tested that combination. Not in a rat. Not in a dish. Not once. The synergy case is an inference built from two separate literatures that have never been run side by side. It’s coherent. It isn’t evidence.

What does the BPC-157 human trial record actually show?

Strip away the rats and the petri dishes and the human record is short enough to read in a minute. A Phase 1 safety and pharmacokinetics trial, NCT02637284, known by its trial code PCO-02, was registered by the sponsor PharmaCotherapia in 2015. The only published human report since then is a pilot study of two people, an IV-infusion safety pilot run by Lee and Burgess in 2025. Two people. One study.

There’s finally a trial built to answer a real question instead of just a safety one. NCT07437547 is a Phase 2 randomized, double-blind, placebo-controlled trial testing BPC-157 for acute hamstring strain, the first registered controlled human trial to target an injury-recovery use rather than pure safety. It’s recruiting. It hasn’t reported. Until it does, the entire human case for BPC-157 rests on two people and a decade-old safety file.

TB-500: Is the synthetic fragment equivalent to the full thymosin beta-4 protein?

Thymosin beta-4 is a 43-residue protein your own cells make, a G-actin binding peptide that helps a cell hold its shape and crawl toward damage. TB-500 is the synthetic version of it, sold on the assumption that a shorter, cheaper synthetic peptide can substitute for the full protein without losing potency.

Philp and Kleinman’s 2010 review in the Annals of the New York Academy of Sciences rounded up decades of that biology in animals: actin binding, cell migration, recruitment to a wound. Sosne and colleagues ran a 2002 mouse corneal-injury study and saw the same signal in eye tissue. Wu and colleagues, in 2020, loaded thymosin beta-4 into an electrospun scaffold material and watched it behave the way the biology predicted.

None of those three studies used TB-500. They used the parent protein, or engineered constructs built from it. Whether the synthetic peptide behaves the same way once it’s in a human body is the actual question, and nobody has published the trial that answers it. TB-500 has zero human trials of any kind, safety or efficacy. None.

Two unproven peptides together: multiply the case or the unknowns?

Each compound carries its own hole in the file. BPC-157 has one small human safety pilot (Lee & Burgess, 2025) and a decade-old Phase 1 trial (NCT02637284), with a Phase 2 trial still recruiting. TB-500 has no human trial record at all, not for safety, not for anything else.

Put the two in the same syringe and the unknowns don’t average out. If BPC-157 alone has an open question about IV safety at scale, and TB-500 alone has never been tested in a person, combining them doesn’t split the difference into something more reassuring. It stacks one unanswered question on top of another.

The compounding crackdown, and what evaluation means inside it

No FDA-approved drug application exists for either peptide. That’s the blank space on the label both vials share. A PCAC recommendation means a compounding pharmacy might, eventually, be allowed to handle the substance under the FDA’s compounding framework, if the FDA follows the committee’s advice. It isn’t a green light today. PCAC recommended both BPC-157 and TB-500 at the July 23–24, 2026 meeting; the door opened partway. FDA final action, the part that actually changes what a pharmacy can legally do, is still pending.

TB-500 got the same recommendation. Same open legal question, same absence of FDA approval, attached to a peptide with an even thinner human record than BPC-157’s. A compounding pharmacy reading this docket sees two substances that cleared PCAC on separate votes, not one endorsed protocol.

What to do with a docket, not a verdict

A clinician or an informed reader looking at this file has one honest read available. The preclinical signal for both peptides was strong enough that PCAC voted, separately, to recommend each for the 503A list. That’s real. It isn’t nothing. But the leap from recommended for the compounding list to works together hasn’t been made by anyone, in any lab, on any species yet.

The Phase 2 hamstring trial (NCT07437547) will eventually say something about BPC-157 alone. Nothing currently running will say anything about the combination.

Three things can all be true at once. PCAC’s recommendation for both BPC-157 and TB-500 is a genuine regulatory signal, not noise. The mechanistic argument for stacking them is coherent enough to take seriously. And nobody, not the committee, not the pharmacies watching the docket, not the two vials on the shelf, has the human data yet to say the combination does what the theory predicts.